Affordable Access

Access to the full text

Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis

Authors
  • Lough, Tony1
  • Luo, Qingyang1
  • O’Sullivan, Paul1
  • Chemaslé, Christophe2
  • Stotzer, Michael3
  • Suttie, James1
  • Darling, David1
  • 1 Pacific Edge Limited, Dunedin, New Zealand , Dunedin (New Zealand)
  • 2 Mid Central District Health Board, Palmerston North, New Zealand , Palmerston North (New Zealand)
  • 3 Southern District Health Board, Invercargill, New Zealand , Invercargill (New Zealand)
Type
Published Article
Journal
Oncology and Therapy
Publisher
Springer Healthcare
Publication Date
Apr 19, 2018
Volume
6
Issue
1
Pages
73–85
Identifiers
DOI: 10.1007/s40487-018-0059-5
Source
Springer Nature
Keywords
License
Yellow

Abstract

IntroductionInternational guidelines advocate regular surveillance of patients following urothelial carcinoma (UC). A validated molecular diagnostic non-invasive urine test, Cxbladder Monitor, correctly identifies patients with a UC history who have low-probability of recurrence. The present study assesses the clinical utility of Cxbladder Monitor in reducing the number and frequency of urologic procedures ordered without missing detection of recurrent UC.MethodsData from 828 physician–patient assessments were generated from 18 participant physicians who each evaluated the same real-world clinical case data for 30 patients undergoing surveillance for recurrent UC. Each physician ordered tests and procedures and their timing, following review of the patient’s demographic data, pre-existing conditions, risk factors and clinical history before and after disclosure of Cxbladder Monitor results. Changes in the number, type and timing of procedures ordered were assessed.ResultsThe addition of Cxbladder Monitor significantly reduced the overall number of tests ordered by 38.7%, including flexible cystoscopy by 43%, for patients whose Cxbladder Monitor result was low-probability. When the result was elevated-probability, the number of procedures ordered, including cystoscopy, was increased consistent with the increased risk of recurrent UC. Importantly, based on the tests ordered by each physician for each of the patients, all cases of recurrent UC would have been detected.ConclusionThe increase in clinical utility of Cxbladder Monitor for the management of patients undergoing surveillance for recurrent UC was shown to be driven by the reduction in procedures ordered for low-probability patients and for the more invasive procedures ordered for elevated-probability patients. In this study, the total number of procedures ordered, including the number of cystoscopies, was reduced especially in patients with low-probability of UC. The invasive procedures were ordered in a more targeted fashion for elevated-probability patients, without compromising the detection of recurrent UC.Clinicaltrials.gov IdentifierNCT02700659.FundingPacific Edge Limited.

Report this publication

Statistics

Seen <100 times